Abstract #9686 Poster # LB-133 RGENIX

Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors

Monica Mita¹, Alan Mita¹, Erika Hamilton², Gerald S. Falchook³, Michael Postow⁴, Bartosz Chmielowski⁵, Russell J. Schilder⁶, James Strauss⁷, Emerson Lim⁸, Shubham Pant⁹, Angela Jain¹⁰, Oliver Rixe¹¹, Rebecca Redman¹², Kevin B. Kim¹³, Tomislav Dragovich¹⁴, R. Donald Harvey¹⁵, Igor Puzanov¹⁶, Nimisha Schneider¹⁷, Renee Deehan¹⁷, Tobi Guennel¹⁷, Joe Lin¹⁷, Sohail Tavazoie¹⁸, Roger Waltzman¹⁹, Robert Busby¹⁹, Narayan Lebaka¹⁹, Robert Busby¹⁹, Narayan Lebak¹⁹, Robert Busby¹⁹, Narayan Lebak¹⁹, Robert Busby¹⁹, Narayan Lebak¹⁹, Robert Busby¹⁹, Robert Busb ¹Cedars-Sinai Medical Center, Los Angeles, CA; ²Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; ³Sarah Cannon Research Institute/Te

